Advertisement

Drugs

, Volume 78, Issue 18, pp 1913–1924 | Cite as

Enzalutamide: A Review in Castration-Resistant Prostate Cancer

  • Lesley J. Scott
Adis Drug Evaluation

Abstract

Oral enzalutamide (Xtandi®), a second generation androgen receptor inhibitor, is indicated for the treatment of castration-resistant prostate cancer (CRPC) in numerous countries worldwide, with specific indications in this patient population varying between individual countries. Based on extensive experience in the clinical trial and/or real-world settings, oral enzalutamide 160 mg once daily is an effective and generally well tolerated treatment in a broad spectrum of patients with CRPC, including in nonmetastatic and metastatic disease and in chemotherapy-naive and -experienced metastatic CRPC. Enzalutamide is an emerging option for the treatment of men with nonmetastatic CRPC who are at high-risk for developing metastatic disease, and remains an important first-line option in chemotherapy-naive or -experienced patients with metastatic CRPC.

Notes

Acknowledgements

During the peer review process, the manufacturer of enzalutamide was also offered an opportunity to review this article. Changes resulting from comments received were made on the basis of scientific and editorial merit.

Compliance with Ethical Standards

Funding

The preparation of this review was not supported by any external funding.

Conflicts of interest

Lesley Scott is a salaried employee of Adis/Springer, is responsible for the article content and declares no relevant conflicts of interest.

References

  1. 1.
    Attard G, Parker C, Eeles RA, et al. Prostate cancer. Lancet. 2016;387:70–82.PubMedGoogle Scholar
  2. 2.
    World Cancer Research Fund International. Prostate cancer statistics. 2018. https://www.wcrf.org/. Accessed 8 Oct 2018.
  3. 3.
    Cornford P, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG guidelines on prostate cancer. Part II: treatment of relapsing, metastatic, and castration-resistant prostate cancer. Eur Urol. 2017;71(4):630–42.PubMedGoogle Scholar
  4. 4.
    NCCN. NCCN Clinical Practice Guidelines in Onoclogy: prostate cancer. 2017. https://www.nccn.org/. Accessed 17 Nov 2018.
  5. 5.
    Schalken J, Fitzpatrick JM. Enzalutamide: targeting the androgen signalling pathway in metastatic castration-resistant prostate cancer. BJU Int. 2016;117(2):215–25.PubMedGoogle Scholar
  6. 6.
    Lorente D, Mateo J, Perez-Lopez R, et al. Sequencing of agents in castration-resistant prostate cancer. Lancet. 2015;16:e279–92.PubMedGoogle Scholar
  7. 7.
    Keating GM. Enzalutamide: a review of its use in chemotherapy-naive metastatic castration-resistant prostate cancer. Drugs Aging. 2015;32(3):243–9.PubMedGoogle Scholar
  8. 8.
    Sanford M. Enzalutamide: a review of its use in metastatic, castration-resistant prostate cancer. Drugs. 2013;73(15):1723–32.PubMedGoogle Scholar
  9. 9.
    Tran C, Ouk S, Clegg NJ, et al. Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science. 2009;324(5928):787–90.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Baciarello G, Sternberg CN. Treatment of metastatic castration-resistant prostate cancer (mCRPC) with enzalutamide. Crit Rev Oncol Hematol. 2016;106:14–24.PubMedGoogle Scholar
  11. 11.
    Astellas Pharma US Inc. Xtandi® (enzalutamide) capsules, for oral use: US prescribing information. 2018. https://www.astellas.us/. Accessed 12 Nov 2018.
  12. 12.
    European Medicines Agency. Xtandi (enzalutamide): summary of product characteristics. 2018. http://www.ema.europa.eu. Accessed 12 Nov 2018.
  13. 13.
    Gibbons JA, de Vries M, Krauwinkel W, et al. Pharmacokinetic drug interaction studies with enzalutamide. Clin Pharmacokinet. 2015;54(10):1057–69.PubMedPubMedCentralGoogle Scholar
  14. 14.
    Gibbons JA, Ouatas T, Krauwinkel W, et al. Clinical pharmacokinetic studies of enzalutamide. Clin Pharmacokinet. 2015;54(10):1043–55.PubMedPubMedCentralGoogle Scholar
  15. 15.
    Antonarakis ES, Lu C, Luber B, et al. Clinical significance of androgen receptor splice variant-7 mRNA detection in circulating tumor cells of men with metastatic castration-resistant prostate cancer treated with first- and second-line abiraterone and enzalutamide. J Clin Oncol. 2017;35(19):2149–56.PubMedPubMedCentralGoogle Scholar
  16. 16.
    Seitz AK, Thoene S, Bietenbeck A, et al. AR-V7 in peripheral whole blood of patients with castration-resistant prostate cancer: association with treatment-specific outcome under abiraterone and enzalutamide. Eur Urol. 2017;72(5):828–34.PubMedGoogle Scholar
  17. 17.
    Qu F, Xie W, Nakabayashi M, et al. Association of AR-V7 and prostate-specific antigen RNA levels in blood with efficacy of abiraterone acetate and enzalutamide treatment in men with prostate cancer. Clin Cancer Res. 2017;23(3):726–34.PubMedGoogle Scholar
  18. 18.
    Scher HJ, Graf RP, Hulling M, et al. Use of nuclear-localized androgen receptor splice variant 7 protein in CTCs after 1st androgen receptor signaling inhibitor (ARSi) as a predictive biomarker for overall survival on a second ARSi or taxane chemotherapy in metastatic castration-resistant prostate cancer (mCRPC) [abstract no. 836P]. Ann Oncol. 2018;29(Suppl 8):viii292.Google Scholar
  19. 19.
    Hussain M, Fizazi K, Saad F, et al. Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer. N Engl J Med. 2018;378(26):2465–74.PubMedGoogle Scholar
  20. 20.
    Fizazi K, Hussain M, Saad F, et al. A phase III randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (MO) castration-reistant prostate cancer (CRPC): results of PROSPER by age and region [abstract no. 805P]. Ann Oncol. 2018;29(Suppl 8):viii277.Google Scholar
  21. 21.
    Shore N, Saad F, Hussain M, et al. The PROSPER trial: chemotherapy-related endpoints in patients with nonmetastatic castration-resistant prostate cancer treated with enzalutamide [abstract no. PD10-09]. J Urol. 2018;199(4 Suppl):e231.Google Scholar
  22. 22.
    Tombal B, Hussain A, Penson D, et al. Prolonged urinary and bowel symptom control in men with nonmetastatic castration-resistant bowel cancer (nmCRPC) treated with enzaluatmide: results from the PROSPER study [abstract no. 807P]. Ann Oncol. 2018;29(Suppl 8):viii278.Google Scholar
  23. 23.
    Saad F, Penson D, Attard G, et al. Impact of enzalutamide on pain and health-related quality of life in men with non-metastatic castration-resistant prostate cancer: PROSPER study results [abstract no. MP52-19]. J Urol. 2018;199(4 Suppl):e703.Google Scholar
  24. 24.
    Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424–33.PubMedPubMedCentralGoogle Scholar
  25. 25.
    Shore ND, Chowdhury S, Villers A, et al. Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study. Lancet Oncol. 2016;17(2):153–63.PubMedGoogle Scholar
  26. 26.
    Rathkopf DE, Beer TM, Loriot Y, et al. Radiographic progression-free survival as a clinically meaningful end point in metastatic castration-resistant prostate cancer: the PEVAIL randomized clinical trial. JAMA Oncol. 2018;4(5):694–701.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Beer TM, Armstrong AJ, Rathkopf D, et al. Enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer: extended analysis of the phase 3 PREVAIL study. Eur Urol. 2017;71(2):151–4.PubMedGoogle Scholar
  28. 28.
    Graff JN, Baciarello G, Armstrong AJ, et al. Efficacy and safety of enzalutamide in patients 75 years or older with chemotherapy-naive metastatic castration-resistant prostate cancer: results from PREVAIL. Ann Oncol. 2016;27(2):286–94.PubMedGoogle Scholar
  29. 29.
    Evans CP, Higano CS, Keane T, et al. The PREVAIL study: primary outcomes by site and extent of baseline disease for enzalutamide-treated men with chemotherapy-naive metastatic castration-resistant prostate cancer. Eur Urol. 2016;70(4):675–83.PubMedGoogle Scholar
  30. 30.
    Alumkal JJ, Chowdhury S, Loriot Y, et al. Effect of visceral disease site on outcomes in patients with metastatic castration-resistant prostate cancer treated with enzalutamide in the PREVAIL trial. Clin Genitourin Cancer. 2017;15(5):610.e3–617.e3.Google Scholar
  31. 31.
    Kim CS, Choi YD, Lee SE, et al. Post hoc analyses of East Asian patients from the randomized placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer. Medicine. 2017;96(27):e7223.PubMedPubMedCentralGoogle Scholar
  32. 32.
    Kimura G, Yonese J, Fukagai T, et al. Enzalutamide in Japanese patients with chemotherapy-naive, metastatic castration-resistant prostate cancer: a post-hoc analysis of the placebo-controlled PREVAIL trial. Int J Urol. 2016;23(5):395–403.PubMedGoogle Scholar
  33. 33.
    Kimura G, Ueda T. Post hoc analysis of Japanese patients from the placebo-controlled PREVAIL trial of enzalutamide in patients with chemotherapy-naive, metastatic castration-resistant prostate cancer-updated results. Jpn J Clin Oncol. 2017;47(3):262–4.PubMedGoogle Scholar
  34. 34.
    Kim CS, Theeuwes A, Kwon DD, et al. The PREVAIL trial of enzalutamide in men with chemotherapy-naive, metastatic castration-resistant prostate cancer: post hoc analysis of Korean patients. Investig Clin Urol. 2016;57(3):174–83.PubMedPubMedCentralGoogle Scholar
  35. 35.
    Taplin M-E, Armstrong AJ, Lin P, et al. Clinical outcomes of chemotherapy naive men with metastatic castration resistant prostate cancer and low baseline prostate specific antigen treated with enzalutamide vs placebo. J Urol. 2017;198(6):1324–32.PubMedGoogle Scholar
  36. 36.
    Skaltsa K, Ivanescu C, Naidoo S, et al. Adjusting overall survival after treatment switching: a case study in metastatic castration-resistant prostate cancer. Targ Oncol. 2017;12:111–21.Google Scholar
  37. 37.
    Bryce AH, Alumkal JJ, Armstrong A, et al. Radiographic progression with nonrising PSA in metastatic castration-resistant prostate cancer: post hoc analysis of PREVAIL. Prostate Cancer Prostat Dis. 2017;20:221–7.Google Scholar
  38. 38.
    Loriot Y, Miller K, Sternberg CN, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16(5):509–21.PubMedGoogle Scholar
  39. 39.
    Devlin N, Herdman M, Pavesi M, et al. Health-related quality of life effects of enzalutamide in patients with metastatic castration-resistant prostate cancer: an in-depth post hoc analysis of EQ-5D data from the PREVAIL trial. Health Qual Life Outcomes. 2017;15(130):1–9.Google Scholar
  40. 40.
    Beer TM, Miller K, Tombal B, et al. The asscoiation between health-related quality-of-life scores and clinical outcomes in metastatic castration-resistant prostate cancer patients: exploratory analyses of AFFIRM and PREVAIL studies. Eur J Cancer. 2017;87:21–9.PubMedGoogle Scholar
  41. 41.
    Saad F, Ivanescu C, Phung D, et al. Skeletal-related events significantly impact health-related quality of life in metastatic castration-resistant prostate cancer: data from PREVAIL and AFFIRM trials. Prostate Cancer Prostat Dis. 2017;20:110–6.Google Scholar
  42. 42.
    Siemens DR, Klotz L, Heidenreich A, et al. Efficacy and safety of enzalutamide vs bicalutamide in younger and older patients with metastatic castration resistant prostate cancer in the TERRAIN trial. J Urol. 2018;199(1):147–54.PubMedGoogle Scholar
  43. 43.
    Heidenreich A, Chowdhury S, Klotz L, et al. Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial. Eur Urol. 2017;71(4):534–42.PubMedGoogle Scholar
  44. 44.
    Schultz NM, Shore ND, Chowdhury S, et al. Number-needed-to-treat analysis of clinical progression in patients with metastatic castration-resistant prostate cancer in the STRIVE and TERRAIN trials. BMC Urol. 2018;18:77.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012;367(13):1187–97.PubMedGoogle Scholar
  46. 46.
    Loriot Y, Fizazi K, de Bono JS, et al. Enzalutamide in castration-resistant prostate cancer patients with visceral disease in the liver and/or lung: outcomes from the randomized controlled phase 3 AFFIRM trial. Cancer. 2017;123(2):253–62.PubMedGoogle Scholar
  47. 47.
    Sternberg CN, de Bono JS, Chi KN, et al. Improved outcomes in elderly patients with metastatic castration-resistant prostate cancer treated with the androgen receptor inhibitor enzalutamide: results from the phase III AFFIRM trial. Ann Oncol. 2014;25(2):429–34.PubMedGoogle Scholar
  48. 48.
    Saad F, de Bono J, Shore N, et al. Efficacy outcomes by baseline prostate-specific antigen quartile in the AFFIRM trial. Eur Urol. 2015;67(2):223–30.PubMedGoogle Scholar
  49. 49.
    Armstrong AJ, Saad F, Phung, et al. Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxel. Cancer. 2017;123(12):2303–11.PubMedPubMedCentralGoogle Scholar
  50. 50.
    Fizazi K, Scher HI, Miller K, et al. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial. Lancet Oncol. 2014;15(10):1147–56.PubMedGoogle Scholar
  51. 51.
    Cella D, Ivanescu C, Holmstrom S, et al. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol. 2015;26(1):179–85.PubMedGoogle Scholar
  52. 52.
    de Bono JS, Chowdhury S, Feyerabend S, et al. Antitumour activity and safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with abiraterone acetate plus prednisone for ≥ 24 weeks in Europe. Eur Urol. 2018;74(1):37–45.PubMedGoogle Scholar
  53. 53.
    Penson DF, Armstrong AJ, Concepcion R, et al. Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE trial. J Clin Oncol. 2016;34(18):2098–106.PubMedGoogle Scholar
  54. 54.
    Penson DF, Armstrong AJ, Concepcion RS, et al. Sensitivity analyses for progression-free survival (PFS) and radiographic PFS (rPFS) from the phase II STRIVE trial comparing enzalutamide (ENZA) with bicalutamide (BIC) in men with castration-resistant prostate cancer (CRPC) [abstract no. 169]. J Clin Oncol. 2016;34(2 Suppl):e169.Google Scholar
  55. 55.
    Thiery-Vuillemin A, Hvid Poulsen M, Lagneau E, et al. Impact of abiraterone acetate plus prednisone or enzalutamide on fatigue and cognition in patients with metastatic castration-resistant prostate cancer: initial results from the observational AQUARiUS study. ESMO Open. 2018;3(5):e000397.PubMedPubMedCentralGoogle Scholar
  56. 56.
    Miyake H, Hara T, Terakawa T, et al. Comparative assessment of clinical outcomes between abiraterone acetate and enzalutamide in patients with docetaxel-naive metastatic castration-resistant prostate cancer: experience in real-world clinical practice in Japan. Clin Genitourin Cancer. 2017;15(2):313–9.PubMedGoogle Scholar
  57. 57.
    Flaig TW, Potluri RC, Ng Y, et al. Treatment evolution for metastatic castration-resistant prostate cancer with recent introduction of novel agents: retrospective analysis of real-world data. Cancer Med. 2016;5(2):182–91.PubMedGoogle Scholar
  58. 58.
    Pilon D, Behl AS, Ellis LA, et al. Duration of treatment in prostate cancer patients treated with abiraterone acetate or enzalutamide. J Manag Care Spec Pharm. 2017;23(2):225–35.PubMedGoogle Scholar
  59. 59.
    Behl AS, Ellis LA, Pilon D, et al. Medication adherence, treatment patterns, and dose reduction in patients with metastatic castration-resistant prostate cancer receiving abiraterone acetate or enzalutamide. Am Health Drug Benefits. 2017;10(6):296–303.PubMedPubMedCentralGoogle Scholar
  60. 60.
    Cheng HH, Gulati R, Azad A, et al. Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer Prostat Dis. 2015;18(2):122–7.Google Scholar
  61. 61.
    Terada N, Akamatsu S, Okada Y, et al. Factors predicting efficacy and adverse effects of enzalutamide in Japanese patients with castration-resistant prostate cancer: results of retrospective multi-institutional study. Int J Clin Oncol. 2016;21(6):1155–61.PubMedGoogle Scholar
  62. 62.
    Moses KA, Penson DF, Schultz NM, et al. Real-world study of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate plus prednisone (AA+P): patient characteristics and treatment persistence [abstract no. e16542]. J Clin Oncol. 2017;35(15 Suppl):112.Google Scholar
  63. 63.
    Maines F, De Giorgi U, Procopio G, et al. Enzalutamide after chemotherapy in advanced castration-resistant prostate cancer: the Italian Named Patient Program. Fut Oncol. 2018.  https://doi.org/10.2217/fon-2018-0113.Google Scholar
  64. 64.
    Joshua AM, Shore ND, Saad F, et al. Safety of enzalutamide in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel: expanded access in North America. Prostate. 2015;75(8):836–44.PubMedPubMedCentralGoogle Scholar
  65. 65.
    Slovin S, Clark W, Carles J, et al. Seizure rates in enzalutamide-treated men with metastatic castration-resistant prostate cancer and risk of seizure: the UPWARD study. JAMA Oncol. 2017;4(5):702–6.PubMedCentralGoogle Scholar
  66. 66.
    Dharmani C, Bonafede M, Krivoshik A. Risk factors for and incidence of seizures in metastatic castration-resistant prostate cancer: a real-world retrospective cohort study. Clin Drug Invest. 2017;37:1183–90.Google Scholar
  67. 67.
    Azad A, Saad F, Chowdhury S, et al. Fatigue in men with metastatic castration-resistant prostate cancer treated with enzalutamide: data from randomized clinical trials [abstract no. 102]. Asia Pac J Clin Oncol. 2017;13(Suppl 1):41.Google Scholar
  68. 68.
    Quek RGW, Gilligan AM, Kent ST, et al. Hospital admissions (HA) among chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC) patients newly treated with enzalutamide (ENZA) or abiraterone (ABI) [abstract no. e16524]. J Clin Oncol. 2017;35:15 Suppl.Google Scholar
  69. 69.
    Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA guideline. 2018. https://www.auanet.org/. Accessed 15 Oct 2018.
  70. 70.
    European Medicines Agency. Meeting highlights from the Committee for Medicinal Products for Human use (CHMP) 12–15 November 2018. 2018. http://www.ema.europa.eu. Accessed 26 Nov 2018.
  71. 71.
    Benoist GE, Hendriks RJ, Mulders PF, et al. Pharmacokinetic aspects of the two novel oral drugs used for metastatic castration-resistant prostate cancer: abiraterone acetate and enzalutamide. Clin Pharmacokinet. 2016;55(11):1369–80.PubMedPubMedCentralGoogle Scholar
  72. 72.
    Scott LJ. Abiraterone acetate: a review in metastatic castration-resistant prostate cancer. Drugs. 2017;77(14):1565–76.PubMedGoogle Scholar
  73. 73.
    McCool R, Fleetwood K, Glanville J, et al. Systematic review and network meta-analysis of treatments for chemotherapy-naive patients with asymptomatic/mildly symptomatic metastatic castration-resistant prostate cancer. Value Health. 2018.  https://doi.org/10.1016/j.jval.2018.03.012.PubMedGoogle Scholar
  74. 74.
    Kang M, Jeong CW, Kwak C, et al. Comparing the clinical efficacy of abiraterone acetate, enzalutamide, and orteronel in patients with metastatic castration-resistant prostate cancer by performing a network meta-analysis of eight randomized controlled trials. Oncotarget. 2017;8(35):59690–7.PubMedPubMedCentralGoogle Scholar
  75. 75.
    Rizzo S, Galvano A, Pantano F, et al. The effects of enzalutamide and abiraterone on skeletal related events and bone radiological progression free survival in castration resistant prostate cancer patients: an indirect comparison of randomized controlled trials. Critic Rev Oncol-Hematol. 2017;120:227–33.Google Scholar
  76. 76.
    Chopra A, Georgieva M, Lopes G, et al. Abiraterone or enzalutamide in advanced castration-resistant prostate cancer: an indirect comparison. Prostate. 2017;77(6):639–46.PubMedGoogle Scholar
  77. 77.
    Fang M, Nakazawa M, Antonarakis ES, et al. Efficacy of abiraterone and enzalutamide in pre- and postdocetaxel castration-resistant prostate cancer: a trial-level meta-analysis. Prostate Cancer. 2017;2017:8560827.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Crawford ED, Higano CS, Shore ND, et al. Treating patients with metastatic castration reistant prostate cancer: a comprehensive review of available therapies. J Urol. 2015;194:1537–47.PubMedGoogle Scholar
  79. 79.
    Hornberger J, Graf RP, Hulling M, et al. Overall survival (OS) implications for patients with mCRPC through coverage and adoption of nuclear AR-V7 testing by healthcare systems [abstract no. 848P]. Ann Oncol. 2018;29(Suppl 8):viii296.Google Scholar
  80. 80.
    NICE. Enzalutamide for treating metasatic hormone-relapsed prostate cancer before chemotherapy is indicated: TA377. 2016. http://www.nice.org.uk. Accessed 12 Nov 2018.
  81. 81.
    NICE. Enzalutamide for metastatic hormone-relapsed prostate cancer previously treated with a docetaxel-containing regimen: TA316. 2014. http://www.nice.org.uk. Accessed 12 Nov 2018.
  82. 82.
    Massoudi M, Balk M, Yang H, et al. Number needed to treat and associated incremental costs of treatment with enzalutamide versus abiraterone acetate plus prednisone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. J Med Econ. 2017;20(2):121–8.PubMedGoogle Scholar
  83. 83.
    Schultz NM, Flanders SC, Wilson S, et al. Treatment duration, healthcare resource utilization, and costs among chemotherapy-naive patients with metasatic castration-resistant prostate cancer treated with enzalutamide or abiraterone acetate: a retrospective claims analysis. Adv Ther. 2018.  https://doi.org/10.1007/s12325-018-0774-1.PubMedPubMedCentralGoogle Scholar
  84. 84.
    Bui CN, O’Day K, Flanders S, et al. Budget impact of enzalutamide for chemotherapy-naive metastatic castration-resistant prostate cancer. J Manag Care Spec Pharm. 2016;22(2):163–70.PubMedGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  1. 1.SpringerAucklandNew Zealand

Personalised recommendations